Cizumab (bevacizumab biosimilar) / Hetero - LARVOL DELTA

Second-line Treatment Strategy in Unresectable Hepatocellular Carcinoma After First-line Atezolizumab Plus Bevacizumab. (PubMed, Anticancer Res) - "Lenvatinib is useful as second-line treatment after Ate/Bev for uHCC patients who do not response to Ate/Bev treatment. Changes in serum FGF-19 levels after three weeks of AteBev therapy may serve as a biomarker for selecting lenvatinib as second-line therapy."

Journal • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • FGF • FGF19

INTRACEREBRAL HAEMORRHAGE RELATED TO DIRECT ORAL ANTICOAGULANTS – RESULTS OF THE PROSPECTIVE RASUNOA-PRIME STUDY (WSC 2023) - P=N/A | "Among 356 DOAC-ICH patients, 30.1% received no reversal agent, 59.6 % PCC and 10.4% idaru-cizumab/andexanet alfa. Our prospective study shows a higher risk of hematoma growth in DOAC versus no-OAC. Hematoma volume and clinical deficits were similar early after symptom-onset suggesting a window of opportunity for haemostatic interventions."

Clinical • Atrial Fibrillation • Cardiovascular

A Real-World Study of Safety, Immunogenicity and Efficacy of Bevacizumab in Patients With Solid Malignancies: A Phase IV, Post-Marketing Study in India. (PubMed, Cancer Inform) - "Bevacizumab (Cizumab, Hetero Biopharma) was observed to be safe, well tolerated, lacking immunogenicity, and efficacious in the treatment of solid tumors. The findings of this phase IV study of Bevacizumab, primarily as a combination therapy regimen suggest its suitability and rationality for usage in multiple solid malignancies. CTRI/2018/4/13371 [Registered on CTRI http://ctri.nic.in/Clinicaltrials/advsearch.php : 19/04/2018]; Trial Registered Prospectively."

Journal • P4 data • Real-world • Real-world evidence • Cervical Cancer • Colorectal Cancer • Gastroenterology • Gastrointestinal Cancer • Gastrointestinal Disorder • Genito-urinary Cancer • Hematological Disorders • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Neutropenia • Non Small Cell Lung Cancer • Oncology • Pain • Renal Cell Carcinoma • Solid Tumor

A POOLED ANALYSIS FROM PHASE III CLINICAL TRIALS TO INVESTIGATE THE INCIDENCE OF BREAST CANCER (BC) IN BRCA-RELATED ADVANCED OVARIAN CANCER (AOC) DURING OLAPARIB-BASED MAINTENANCE THERAPY (AIOM 2022) - "Patients in the sperimental arms were treated with olaparib +/- beva- cizumab (n= 788), while patients in the control arms had received placebo or standard therapies (n = 398). In clinical trials of PARPi in BRCA-related AOC, the incidence of second primary BC was low sug- gesting that intensive screening should be avoided at least in early treatment phase. Population-based data are needed to better define BC risk and surveillance strategy."

P3 data • Retrospective data • Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • BRCA • BRCA1 • BRCA2

Novel approach to antiangiogenic factors in age-related macular degeneration therapy. (PubMed, Cent Eur J Immunol) - "Among the directions in dry AMD treatment, the most promising are complement cascade inhibitors and complement cascade targeted gene therapy. In the article we outline the main directions in up-to-date experimental and practical approaches to wet and dry AMD therapy with the emphasis on antiangiogenic factors and gene therapy focused on the inhibition of pathological angiogenesis."

Journal • Review • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

"I-dare-you-cizumab." (@salvadorpayan)

[VIRTUAL] Major non elective orthopaedic surgery on a severe haemophilia A patient on emicizumab (without inhibitors): a case study (BSH 2021) - "These included bovine chromogenic FVIII (101.2 IU/dl) and an emi- cizumab level (45.9 µg/ml)...Pre-operative peak FVIII level of ~100 IU/dL was achieved (2000 IU Refacto AF)...This case highlights the importance of tailoring haemostatic plans according to the patient. Fur- thermore we may be able to safely use shorter courses of factor replace- ment alongside emicizumab following major orthopaedic surgery."

Clinical • Hematological Disorders • Hemophilia • Musculoskeletal Diseases • Orthopedics • Pain • Rare Diseases

Rationale and Design of a Randomized Phase 2 Trial of Gefitinib Plus Bevacizumab vs Gefitinib Alone in Patients with Epidermal Growth Factor Receptor Mutant Non-Squamous Non-Small-Cell Lung Cancer: Study Protocol. (PubMed, Kurume Med J) - "In this study, subjects will be assigned to receive monotherapy with gefitinib (GEF group) or combination therapy with gefitinib and beva cizumab (GEF+BEV group) as the initial treatment at a ratio of 1:1. EGFR gene mutations are frequently detected in Asian patients with non-small-cell lung cancer. This study may be significant for establishing a new standard treatment."

Clinical • Journal • P2 data